A contract manufacturing organization (CMO) or contract development and manufacturing organization (CDMO), is a company that serves other companies in the pharmaceutical industry on a contract basis to provide comprehensive services from drug development through drug manufacturing. This allows major pharmaceutical companies to outsource those aspects of the business, which can help with scalability or can allow the major company to focus on drug discovery and drug marketing instead.
Services offered by CMOs include, but are not limited to: pre-formulation, formulation development, stability studies, method development, pre-clinical and Phase I clinical trial materials, late-stage clinical trial materials, formal stability, scale-up, registration batches and commercial production. CMOs are contract manufacturers, but they can also be more than that because of the development aspect.

AGC will boost its GMP-compliant pharma production

AGC announced a major expansion of facilities at its Chiba Plant that will result in an increase in the company’s GMP-compliant synthetic pharmaceutical intermediate and active ingredient production capacity.

Novacap acquires PCI Synthesis CDMO

Novacap announced that it has signed an agreement to acquire Boston-based PCI Synthesis, a leading U.S. pharmaceutical contract development and manufacturing organization (CDMO).

Stelis Biopharma and Oncobiologics start a new CDMO

Marketed under the name, Bio2Source, Oncobiologics and Stelis Biopharma will offer development stage biotech companies access to a suite of CDMO services.

Global CDMO Recipharm makes its preparations for Brexit

Recipharm, the contract development and manufacturing organisation (CDMO), has established a dedicated taskforce to manage the potential impact of Brexit on its organisation.

Avara buys the largest sterile manufacturing facility in Canada

Avara Pharmaceutical Services, a world-class contract development and manufacturing organization acquires the largest sterile manufacturing facility for injectable medicines in Canada from a leading global pharmaceutical company.

Recipharm and Hadasit started a partnership

Recipharm, the contract development and manufacturing organisation (CDMO), has partnered with Hadasit Medical Research Services and Development to offer combined clinical, biological and chemical services.

Ardena boosts its API manufacturing capabilities by acquiring Syntagon

Contract development and manufacturing organisation (CDMO) Ardena has acquired Syntagon, a leading contract manufacturer of novel active pharmaceutical ingredients (APIs) and excipients.

Avid Bioservices will expand and optimize its capabilities

Avid Bioservices, a dedicated contract development and manufacturing organization, published an update on the company's ongoing efforts to expand and optimize its process development capabilities and laboratory space.

Sterling Pharma will boost its API manufacturing capabilities

Contract development and manufacturing organisation Sterling Pharma Solutions is investing £6 million (approximately €6,86 million) into its pilot plant facility at its UK site.

Chinese CDMO receives funding to expand GMP manufacturing capabilities

CMAB Biopharma, a Chinese full-service contract development and manufacturing organization (CDMO) providing process development and manufacturing services for biologic products, raised $34 million fin...

Hanmi Pharmaceutical grows as the CDMO market player

hanmi pharmaceutical
South Korean Hanmi Pharmaceutical is progressing quickly on the CDMO market due to its innovations and investments. The Hanmi's Smart Plant was built last year on a 36,492 square meter site.

Rentschler Biopharma and Leukocare reported about effective cooperation

Rentschler Biopharma SE, a leading contract development and manufacturing organization, and Leukocare AG, a biotechnology company, reported on the successful first year of their unique strategic alliance.

iBio expanded its CDMO capabilities for manufacturing of Fc Fusion Proteins

IBio announced the expansion of its CDMO capabilities and services to include the development and cGMP manufacturing of Fc fusion proteins for therapeutic pharmaceutical applications.

Richard Král was appointed as a new CEO of Saneca Pharma CDMO

Richard, who has been the sales and marketing director at Saneca for almost three years, has previously worked for GlaxoSmithKline and Zentiva Group.

Cobra Biologics and Symbiosis received a $2.5 million grant

Cobra Biologics, a contract development and manufacturing organisation of biologics, and Symbiosis Pharmaceutical Services, a contract manufacturing organisation, announced that they have been awarded a collaborative grant

South Korean SK Biotek opens a manufacturing campus in Ireland

SK Biotek has confirmed that it plans to operate and develop Swords Campus as a stand-alone CDMO, which will manufacture pharma products to specification for other pharmaceutical companies on a contract basis